ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple-Negative Breast Cancer to PD-1 Blockade.
Teng Zhou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.